CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models

Surfaceome Profiling of Cell Lines and Patient-Derived Xenografts Confirm FGFR4, NCAM1, CD276, and Highlight AGRL2, JAM3, and L1CAM as Surface Targets for Rhabdomyosarcoma

(2023) Andrea Timpanaro et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance

(2023) Sara G. Danielli et al.   Science Advances

Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy

(2023) Zoya Kurago et al.   Frontiers in Immunology

Cancer statistics, 2022

(2022) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Antitumor responses in gastric cancer by targeting B7H3 via chimeric antigen receptor T cells

(2022) Fengqiang Sun et al.   Cancer Cell International

Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

(2022) J. Joseph Melenhorst et al.   NATURE

An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials

(2022) Josephine H. Haduong et al.   PEDIATRIC BLOOD & CANCER

CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours

(2022) Rebecca C. Larson et al.   NATURE

FGFR4-targeted chimeric antigen receptors (CARs) combined with anti-myeloid poly-pharmacy effectively treats orthotopic rhabdomyosarcoma

(2022) Peter M. Sullivan et al.   MOLECULAR CANCER THERAPEUTICS

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

(2022) Xiaomin Zhang et al.   Frontiers in Immunology

Patient-derived xenografts and organoids model therapy response in prostate cancer

(2021) Sofia Karkampouna et al.   Nature Communications

CAR-T cell therapy: current limitations and potential strategies

(2021) Robert C. Sterner et al.   Blood Cancer Journal

A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains

(2021) Kathryn M. Cappell et al.   Nature Reviews Clinical Oncology

Targeting CD276 by CAR-T cells induces regression of esophagus squamous cell carcinoma in xenograft mouse models

(2021) Yujing Xuan et al.   Translational Oncology

Surfaceome Profiling of Rhabdomyosarcoma Reveals B7-H3 as a Mediator of Immune Evasion

(2021) Roxane R. Lavoie et al.   Cancers

GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity

(2021) Sabine Heitzeneder et al.   CANCER CELL

A High-Throughput Method for Characterizing Novel Chimeric Antigen Receptors in Jurkat Cells

(2020) Darin Bloemberg et al.   Molecular Therapy-Methods & Clinical Development

Chimeric antigen receptor‐modified T‐cell therapy for platelet‐derived growth factor receptor α‐positive rhabdomyosarcoma

(2020) Wei Xiao et al.   CANCER

Tuning the Antigen Density Requirement for CAR T-cell Activity

(2020) Robbie G. Majzner et al.   Cancer Discovery

Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward

(2020) Leila Jafarzadeh et al.   Frontiers in Immunology

Engineering CAR-T Cells for Next-Generation Cancer Therapy

(2020) Mihe Hong et al.   CANCER CELL

Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity

(2020) Gabriele Manzella et al.   Nature Communications

Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia

(2020) Xiangyu Zhao et al.   Molecular Therapy-Oncolytics

CAR T cells targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors

(2019) Robbie G. Majzner et al.   CLINICAL CANCER RESEARCH

Rhabdomyosarcoma

(2019) Stephen X. Skapek et al.   Nature Reviews Disease Primers

Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells

(2019) Hongwei Du et al.   CANCER CELL

A safe and potent anti-CD19 CAR T cell therapy

(2019) Zhitao Ying et al.   NATURE MEDICINE

Emerging trends in immunotherapy for pediatric sarcomas

(2019) Kyle A. Dyson et al.   Journal of Hematology & Oncology

Gene editing for immune cell therapies

(2019) Stefanie R. Bailey et al.   NATURE BIOTECHNOLOGY

B7-H3 as a novel CAR-T therapeutic target for glioblastoma

(2019) Xin Tang et al.   Molecular Therapy-Oncolytics

Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted chimeric antigen receptor-T cells for B-cell non-Hodgkin lymphoma

(2019) Zhitao Ying et al.   Molecular Therapy-Oncolytics

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

(2019) Sarwish Rafiq et al.   Nature Reviews Clinical Oncology

Hedgehog Pathway Drives Fusion-Negative Rhabdomyosarcoma Initiated From Non-myogenic Endothelial Progenitors

(2018) Catherine J. Drummond et al.   CANCER CELL

Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia

(2018) Franziska Blaeschke et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector

(2018) Eric L. Smith et al.   MOLECULAR THERAPY

Chimeric Antigen Receptor Therapy

(2018) Carl H. June et al.   NEW ENGLAND JOURNAL OF MEDICINE

CAR T cell immunotherapy for human cancer

(2018) Carl H. June et al.   SCIENCE

In vivo fate and activity of second versus third-generation D19-specific CAR-T cells in B-cell non-Hodgkin lymphomas

(2018) Carlos A. Ramos et al.   MOLECULAR THERAPY

Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function

(2018) Alexander I. Salter et al.   Science Signaling

TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action

(2017) Wenwen Du et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase

(2017) Alec J. Walker et al.   MOLECULAR THERAPY

GUIDES: sgRNA design for loss-of-function screens

(2017) Joshua A Meier et al.   NATURE METHODS

Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children

(2017) Michael Merker et al.   Oncotarget

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

(2016) Omkar U. Kawalekar et al.   IMMUNITY

BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models

(2016) Yuki Kagoya et al.   JOURNAL OF CLINICAL INVESTIGATION

649. Developing FGFR4 Chimeric Antigen Receptor CAR T Cell Therapy Against Rhabdomyosarcoma

(2016) Nityashree Shivaprasad et al.   MOLECULAR THERAPY

Modulation of mTOR Signalling Triggers the Formation of Stem Cell-like Memory T Cells

(2016) Godehard Scholz et al.   EBioMedicine

Cellular immunotherapy for pediatric solid tumors

(2015) Meenakshi Hegde et al.   CYTOTHERAPY

CAR T-cell therapy: toxicity and the relevance of preclinical models

(2015) Milena Kalaitsidou et al.   Immunotherapy

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

The pharmacology of second-generation chimeric antigen receptors

(2015) Sjoukje J. C. van der Stegen et al.   NATURE REVIEWS DRUG DISCOVERY

In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells

(2015) Luca Biasco et al.   Science Translational Medicine

IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas

(2015) Xin Huang et al.   PLoS One

Classification of Rhabdomyosarcoma and Its Molecular Basis

(2013) David M. Parham et al.   ADVANCES IN ANATOMIC PATHOLOGY

Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells

(2013) M. Hudecek et al.   CLINICAL CANCER RESEARCH

Design and development of therapies using chimeric antigen receptor-expressing T cells

(2013) Gianpietro Dotti et al.   IMMUNOLOGICAL REVIEWS

B7-H3 is Overexpressed in Patients Suffering Osteosarcoma and Associated with Tumor Aggressiveness and Metastasis

(2013) Ling Wang et al.   PLoS One

A Mouse Model of Rhabdomyosarcoma Originating from the Adipocyte Lineage

(2012) Mark E. Hatley et al.   CANCER CELL

FGFR4 Blockade Exerts Distinct Antitumorigenic Effects in Human Embryonal versus Alveolar Rhabdomyosarcoma

(2012) L. E. S. Crose et al.   CLINICAL CANCER RESEARCH

B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma

(2012) Zhiping Zhou et al.   JOURNAL OF NEURO-ONCOLOGY

Evidence for an Unanticipated Relationship between Undifferentiated Pleomorphic Sarcoma and Embryonal Rhabdomyosarcoma

(2011) Brian P. Rubin et al.   CANCER CELL

Alveolar rhabdomyosarcoma: Is the cell of origin a mesenchymal stem cell?

(2008) Elizabeth Charytonowicz et al.   CANCER LETTERS

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

(2008) Carolina Berger et al.   JOURNAL OF CLINICAL INVESTIGATION

A One Pot, One Step, Precision Cloning Method with High Throughput Capability

(2008) Carola Engler et al.   PLoS One